Opko Health, Inc. is listed today as OPKO Health, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company OPKO Health, Inc., its revenue in fiscal 2025 came from these product and service lines: Transfer of Intellectual Property and Other $79.70 million (13%), Rayaldee $59.39 million (10%).
Annual report (SEC XBRL) · Dec 2025
Opko Health, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Feb 2013).
SEC Form D (revenue range) · Feb 2013
Revenue range over time, as stated in its notices: revenue between $5 million and $25 million in 2009; revenue between $25 million and $100 million in 2013.
SEC Form D (revenue range) · Feb 2013
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2013
Products and services#
No products or services of Opko Health, Inc. are on record.
Investors#
No investor of Opko Health, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today
Institutions holding OPKO Health, Inc. shares, as of Sep 30, 2026.
- Rubric Capital Management LP$77 M6.44%
- BlackRock, Inc.$59 M4.96%
- Vanguard Capital Management LLC$24 M2.00%
- Vanguard Portfolio Management LLC$24 M1.97%
- Geode Capital Management, LLC$18 M1.49%
- State Street Corp$17 M1.43%
- Goldman Sachs Group Inc$13 M1.08%
- Whitefort Capital Management, LP$8 M0.63%
- Charles Schwab Investment Management Inc$6 M0.51%
- Northern Trust Corp$6 M0.50%
- UBS Group AG$5 M0.39%
- Citadel Advisors LLC$4 M0.37%
- Vanguard Fiduciary Trust Co$4 M0.37%
- AWM Investment Company, Inc.$3 M0.26%
- Morgan Stanley$3 M0.25%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jane H. Hsiao | Vice Chairman of the Board and Chief Technical Officer | Feb 2013 |
| Juan F. Rodriguez | Senior Vice President and Chief Financial Officer | Feb 2013 |
| Phillip Frost | Chairman of the Board and Chief Executive Officer | Feb 2013 |
| Steven D. Rubin | Executive Vice President-Administration | Feb 2013 |
| Naveed K Shams | Executive officer | Jun 2009 |
| Rao Uppaluri | Executive officer | Jun 2009 |
| Alice Lin-Tsing C. Yu | Director | Feb 2013 |
| Dmitry A. Kolosov | Director | Feb 2013 |
| Jane H. Hsiao | Vice Chairman of the Board and Chief Technical Officer | Feb 2013 |
| John A. Paganelli | Director | Feb 2013 |
| Phillip Frost | Chairman of the Board and Chief Executive Officer | Feb 2013 |
| Richard A. Lerner | Director | Feb 2013 |
| Richard C. Pfenniger, Jr. | Director | Feb 2013 |
| Robert A. Baron | Director | Feb 2013 |
| Steven D. Rubin | Executive Vice President-Administration | Feb 2013 |
| Thomas E. Beier | Director | Feb 2013 |
| Alice Lin-Tsing Yu | Director | Jun 2009 |
| Pascal J. Goldschmidt | Director | Jun 2009 |
Went public since 2011. Its SEC number is that of a company listed on a stock exchange.